Form 8-K Edwards Lifesciences For: Oct 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Form 8-K Edwards Lifesciences For: Oct 24
October 28, 2024 8:19 AM EDT
Bernstein SocGen Group analyst Lee Hambright upgraded Edwards Lifesciences (NYSE: EW) from to Market Perform.
The analyst comments "Our previous Underperform call on EW was based on the view that the TAVR market was experiencing slowing growth and increased competition. Now as... More
October 25, 2024 5:22 AM EDT
BTIG analyst Marie Thibault reiterated a Neutral rating on Edwards Lifesciences (NYSE: EW).
The analyst comments "There were a few moving parts with this quarter's print following the sale of the Critical Care business in September as well as the discontinuation of a small non-core product group in the Surgical Structural Heart business that generates ~$60-70M in annual sales. Excluding these items, EW grew revenue by 9.6% y/y CC in Q3 and reported adj. EPS of $0.67. Total TAVR sales of $1.023B were $13M above consensus of $1.010B (+6.5% y/y rep., +7.2% CC).... More
